All entries

Hemostasis, Thrombosis & Coagulation

• 0036 — What data supports the use of sirolimus in refractory ITP?
• 0034 — Should we perform bone marrow biopsies in patients with ITP?
• 0033 — What is the influence of race and ethnicity on the diagnosis of VWD?
• 0032 — How does congenital dysfibrinogenemia present in women?
• 0031 — What are the mechanisms of acquired von Willebrand syndrome?
• 0030 — What is considered a safe threshold for neuraxial anesthesia in patients with bleeding disorders?
• 0028 — Should patients with antiphospholipid antibody syndrome without thrombotic or obstetric complications receive aspirin for primary prophylaxis?
• 0027 — Can emicizumab be used to treat patients with severe type 3 VWD?
• 0026 — Can persons with hemophilia receive antithrombotic therapy?
• 0021 — How do you diagnose bleeding disorders of unknown cause (BDUC)?
• 0018 — Describe the natural history, definition, diagnosis, investigations, and management of patients with confirmed and suspected VWD.
• 0016 — What treatment options are available for patients with FVII deficiency?
• 0015 — What is your approach to the use of porcine FVIII in acquired hemophilia A?
• 0014 — How do you choose between steroids, cyclophosphamide, and rituximab for inhibitor elimination in acquired hemophilia A?
• 0013 — What is the correlation between factor VIII levels and bleeding in carriers of hemophilia A?
• 0012 — What is the difference between hemophilia carriers and hemophilia?
• 0011 — Can you use TPO-RAs in patients with ITP and positive APLAs?
• 0010 — Can patients with persistent or chronic ITP eventually stop treatment with TPO-RAs?
• 0008 — Is IVIG use in ITP associated with increased risk of thrombosis?
• 0007 — What tests for qualitative platelet function defects do we have available, and how can they influence management in clinic?
• 0006 — In frail elderly patients who are stable on warfarin for stroke prevention from atrial fibrillation, can you switch them to a DOAC? And does that lead to harm?
• 0005 — How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• 0004 — What is the F8 gene duplication (FVIII Padua)?
• 0003 — Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• 0002 — Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• 0001 — Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

General Hematology

• 0037 — Is IV iron safe to administer in acute infections?
• 0035 — What are the bleeding manifestations of vitamin C deficiency?
• 0029 — What are the recommendations for endoscopy in patients presenting with confirmed IDA?
• 0025 — Where can I find a comprehensive review of sickle cell disease?
• 0024 — Outline an approach to neutropenia for acutely ill patients who present to hospital with a normal CBC.
• 0023 — How do you treat severe anemia in individuals who cannot receive blood products?
• 0022 — What are thrombotic microangiopathies?
• 0020 — Where are iron and B12 absorbed in the GI tract?
• 0019 — What is PIMT (persistent isolated mild thrombocytopenia), and is it clinically significant?
• 0017 — Are pre-medications required for IV iron empirically in a patient with a history of anaphylaxis unrelated to the IV iron?
• 0009 — What is the mechanism of iron-induced hypophosphatemia?